A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pharvaris N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 14,472 shares of PHVS stock, worth $346,314. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,472
Previous 238,305 93.93%
Holding current value
$346,314
Previous $5.51 Million 95.06%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$15.67 - $24.59 $3.51 Million - $5.5 Million
-223,833 Reduced 93.93%
14,472 $272,000
Q1 2024

May 15, 2024

BUY
$21.26 - $32.07 $2.06 Million - $3.11 Million
96,847 Added 68.46%
238,305 $5.51 Million
Q4 2023

Feb 14, 2024

BUY
$15.2 - $28.05 $2.15 Million - $3.97 Million
141,458 New
141,458 $3.97 Million

Others Institutions Holding PHVS

About Pharvaris N.V.


  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $808M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.